BridgeBio Pharma, Inc. Form SCHEDULE 13D/A: Amended beneficial ownership report (active)
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-08-17: Form SCHEDULE 13D/A; Description Beneficial ownership report (active); Document xslSCHEDULE_13D_X02/primary_doc.xml.
- 2026-07-10: Form SCHEDULE 13D/A; Description Beneficial ownership report (active); Document xslSCHEDULE_13D_X02/primary_doc.xml.
- 2026-04-02: Form SCHEDULE 13D/A; Description Beneficial ownership report (active); Document xslSCHEDULE_13D_X02/primary_doc.xml.
- 2026-02-17: Form SCHEDULE 13D/A; Description Beneficial ownership report (active); Document xslSCHEDULE_13D_X01/primary_doc.xml.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-08-17 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X02/primary_doc.xml | |
| 2026-07-10 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X02/primary_doc.xml | |
| 2026-04-02 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X02/primary_doc.xml | |
| 2026-02-17 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-11-14 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-08-14 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-07-01 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-05-14 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-03-12 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-03-07 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml | |
| 2025-01-31 | SCHEDULE 13D/A | Beneficial ownership report (active) | xslSCHEDULE_13D_X01/primary_doc.xml |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |